Phase II Combination of Gemcitabine (Fixed Dose-rate Infusion, FDR), Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival rate at five months
Outcome will be measured five months after last evaluable patient is entered on study.
United States: Institutional Review Board
|Abramson Cancer Center at University of Pennsylvania||Philadelphia, Pennsylvania 19104|